Vorozole
Vorozole (developmental code name R-76713; former tentative brand name Rizivor) is an imidazole based competitive inhibitor of the aromatase enzyme. It underwent clinical testing for evaluation for use as an antineoplastic agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent megestrol acetate and research instead focused on the other third generation aromatase inhibitors anastrozole, letrozole and exemestane.[1]
 | |
| Clinical data | |
|---|---|
| Other names | R-76713; Rizivor |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | Very high |
| Metabolism | Hepatic |
| Elimination half-life | 8 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H13ClN6 |
| Molar mass | 324.77 g·mol−1 |
| 3D model (JSmol) | |
| |
  | |
References
- Goss PE (1998). "Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor" (PDF). Breast Cancer Research and Treatment. 49. 49 Suppl 1: S59-65, discussion S73-7. doi:10.1023/a:1006052923468. PMID 9797019.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.